The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
The study will combine cognitive assessments with genetic data and survey responses to gain insights into the causes of these two mental health conditions.
